San Diego-based Erasca, Inc. (Nasdaq: ERAS) announced the pricing of an upsized underwritten public offering of common stock, raising approximately USD 550 million in gross proceeds to fund research and development of its RAS/MAPK pathway oncology pipeline. The deal was upsized from an initial target of USD 500 million announced the same day.
The offering comprised 31,428,572 shares of common stock priced at USD 17.50 per share, with all shares sold directly by Erasca. Underwriters were granted a 30-day option to purchase up to an additional 4,714,285 shares at the offering price, which if exercised in full would increase gross proceeds beyond the USD 550 million base figure. No specific institutional investors were identified in the announcement. Proceeds are directed toward research and development of Erasca's product candidates and for working capital and general corporate purposes.
Erasca's pipeline is anchored by two RAS-targeting assets acquired through in-licensing deals in May 2024. The lead asset, ERAS-0015, is an oral pan-RAS molecular glue licensed from Joyo Pharmatech, currently in Phase I dose escalation in RAS-mutant solid tumors under the AURORAS-1 study. Updated Phase I data released in July 2026 reported an unconfirmed objective response rate of 62% in second-line or later KRAS G12X non-small cell lung cancer patients, and 40–50% unconfirmed ORR in second-line pancreatic ductal adenocarcinoma. The company has indicated plans to initiate registration-enabling trials in lung and pancreatic cancers, with monotherapy expansion cohorts and combination dose escalation cohorts expected to begin in H2 2026. A clinical collaboration with Merck provides pembrolizumab at no cost for combination evaluation within AURORAS-1, reducing Erasca's financial burden for the combination arm.
The second RAS-targeting asset, ERAS-4001, is an oral pan-KRAS inhibitor licensed from Medshine Discovery, currently in Phase I dose escalation under the BOREALIS-1 study, with preliminary monotherapy data expected in H2 2026. Naporafenib, a pan-RAF inhibitor, remains the only Phase III asset through the SEACRAFT-2 trial in NRAS-mutant metastatic melanoma, with Stage 1 randomized data pending. The RAS-targeting franchise has become Erasca's primary value driver following the deprioritization of earlier programs including ERAS-801 and ERAS-007 in 2024.